# Cardiac survival and muscle function > After migration: the PDX Stem Cell follow-up — PDX Stem Cell follows cardiac survival in mice, regenerating fibres with no significant improvement in muscle strength, and a human safety trial. **The arrival question** Cells getting underway make an interesting beginning. A tissue doing its job makes a tougher destination. ## Cardiac and endothelial migration in mice The [mouse cardiac study](https://pubmed.ncbi.nlm.nih.gov/15565145/) connects several observations. Thymosin beta-4 promoted cardiac and endothelial cell migration, formed a functional complex with PINCH and integrin-linked kinase, and activated Akt. After coronary artery ligation, ILK/Akt increased, early myocyte survival improved and cardiac function improved. The work included embryonic and postnatal cardiomyocytes as well as the mouse injury model. Survival interests me at least as much as migration in that account. A departure story naturally makes movement the headline activity. The [cardiac result](https://pubmed.ncbi.nlm.nih.gov/15565145/) gives survival and function their own places beside it. The experiment becomes richer when those observations are retained separately, because movement alone leaves open what happens to the tissue. The molecular names can become an intimidating queue. The reported relationship offers a place to begin: a complex involving PINCH and integrin-linked kinase, with activation of the survival kinase Akt. That description is enough to see why a survival observation appears in the discussion. Establishing precisely how much each activity contributes to the functional outcome would be an additional question, one the appealing overall result should encourage. ## Regenerating fibres and no significant strength improvement In [dystrophin-deficient mdx mice](https://pubmed.ncbi.nlm.nih.gov/20126456/), chronic thymosin beta-4 administration significantly increased the number of regenerating skeletal-muscle fibres. Muscle strength and systolic cardiac function showed no significant improvement. Skeletal and cardiac fibrosis remained elevated. This is a particularly valuable arrival entry: the tissue showed more regeneration by one observation, while muscle strength and systolic cardiac function showed no significant improvement. Regeneration has become a more demanding destination for me after this finding. Which observation earns the word? Here the [fibre finding and the strength finding](https://pubmed.ncbi.nlm.nih.gov/20126456/) diverged. Both deserve to travel with the experiment. Leaving either behind would alter its meaning. It would be a mistake to use this result to erase the favourable mouse cardiac findings. The [cardiac injury experiment](https://pubmed.ncbi.nlm.nih.gov/15565145/) and the [dystrophin-deficient mouse experiment](https://pubmed.ncbi.nlm.nih.gov/20126456/) studied different conditions. Their coexistence makes a useful demand on the question: which tissue, under which conditions, and doing what? I prefer that demanding specificity to a verdict about repair in general. The result also gives the [follicle departure](/follicle) a more interesting companion. [Migration and differentiation accompanied hair growth in rats and mice](https://pubmed.ncbi.nlm.nih.gov/14657002/) in that work. The muscle study reports a different relationship between a regenerative observation and tissue performance. There is room for enthusiasm about the cellular activity and insistence on a defined functional outcome in the same conversation. ![An editorial cross-section illustration of tightly packed muscle fibres with several smaller fibres among them](images/muscle-fibres.webp) *A drawn interpretation of muscle-fibre cross-sections, accompanying the mdx mouse discussion; it supplies no fibre counts or experimental measurements.* ## Healthy volunteers in a Phase 1 study A [randomized, placebo-controlled study in 40 healthy volunteers](https://pubmed.ncbi.nlm.nih.gov/20536472/) examined intravenous synthetic thymosin beta-4 in four cohorts of 10. The study reported infrequent mild or moderate adverse events, no dose-limiting toxicities and no serious adverse events. Pharmacokinetics were dose-proportional, with half-life increasing with dose. This was full-length thymosin beta-4, and the population was healthy volunteers. The human contribution here is a tolerability and pharmacokinetic finding in that population, with a particular preparation. Those observations have value on their own terms. They do not tell me that a fragment will restore someone’s hair, muscle or heart, or establish a longer-term safety profile across clinical populations. The [musculoskeletal narrative review](https://pubmed.ncbi.nlm.nih.gov/41966639/) describes scarce rigorous human safety data for unapproved peptide therapies and potential for serious harm. Its caution deserves to remain beside the encouraging cell and animal experiments. My preferred next destination would be a clearly defined clinical question, with an identified preparation, a useful outcome and attention to harms. That is a wish for further research. The departures in the present collection remain worth studying at their actual scales, even when a human destination is still an open question. --- PDX Stem Cell is my register of connections through published research on cells, an editorial undertaking with no clinic or business service and no medical advice.